| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, UK
1 Professorial Unit of Surgery and Department of Histopathology, Nottingham City Hospital, Nottingham, UK
2 Dipartimento di Medicina Sperimentale e Diagnostica, Universita di Ferrara, Ferrara, Italy
(Requests for offprints should be addressed to J M Gee; Email: gee{at}cardiff.ac.uk)
This paper was presented at the 1st Tenovus/AstraZeneca Workshop, Cardiff (2005). AstraZeneca has supported the publication of these proceedings.
Breast cancer models of acquired tamoxifen resistance, oestrogen receptor (ER)+ /ER– de novo resistance and gene transfer studies cumulatively demonstrate the increased importance of growth factor receptor signalling, notably the epidermal growth factor receptor (EGFR)/HER2, in tamoxifen resistance. Our recent in vitro studies also suggest that EGFR signalling productively cross-talks with insulin-like growth factor receptor (IGF-1R) and, where present, activates ER on key AF-1 serine residues to facilitate acquired tamoxifen-resistant growth. This paper presents our immunohistochemical evidence that EGFR/HER2 signalling (i.e. transforming growth factor (TGF)
, EGFR and HER2 expression; phosphorylation of EGFR, HER2 and ERK1/2 MAP kinase) is also prominent in clinical de novo resistant and modestly increased in acquired tamoxifen-resistant states, suggesting that anti-EGFR/HER2 strategies may prove valuable treatments. Primary breast cancer samples employed were obtained for (1) patients subsequently treated with tamoxifen for advanced disease where endocrine response and survival data were available and (2) ER+ elderly patients during tamoxifen response and relapse. We also present our clinical immunohistochemical findings that IGF-1R expression, its phosphorylation on tyrosine 1316, and also phosphorylation on serine 118 of ER are not only prominent in ER+ tamoxifen-responsive disease, but are also detectable in ER+ de novo and acquired tamoxifen-resistant breast cancer, where there is evidence of EGFR/ER cross-talk. Our data suggest that agents to deplete effectively ER or IGF-1R signalling may be of value in treating ER+ de novo/acquired tamoxifen resistance in addition to tamoxifen-responsive disease in vivo. IGF-1R inhibitors may also prove valuable in ER– patients, since considerable IGF-1R signalling activity was apparent within ~50% of such tumours.
This article has been cited by other articles:
|
|
 |
|
  J. F. R. Robertson, G. G. Steger, P. Neven, S. Barni, F. Gieseking, F. Nole, K. I. Pritchard, F. P. O'Malley, S. D. Simon, B. Kaufman, et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer Ann. Onc., October 29, 2009; (2009) mdp447v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Generali, F. M. Buffa, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Phosphorylated ER{alpha}, HIF-1{alpha}, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer J. Clin. Oncol., January 10, 2009; 27(2): 227 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y.C. Wang, A. L. Stratford, E. Park, J. M.W. Gee, P. Finlay, H. E. Jones, et al. Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival Cancer Res., December 15, 2008; 68(24): 10238 - 10246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Haluska, J. M. Carboni, C. TenEyck, R. M. Attar, X. Hou, C. Yu, M. Sagar, T. W. Wong, M. M. Gottardis, and C. Erlichman HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924 Mol. Cancer Ther., September 1, 2008; 7(9): 2589 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ryan and P. E. Goss The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer Oncologist, January 1, 2008; 13(1): 16 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jiang, N. Sarwar, D. Peston, E. Kulinskaya, S. Shousha, R. C. Coombes, and S. Ali Phosphorylation of Estrogen Receptor-{alpha} at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients Clin. Cancer Res., October 1, 2007; 13(19): 5769 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Haluska, H. M. Shaw, G. N. Batzel, D. Yin, J. R. Molina, L. R. Molife, T. A. Yap, M. L. Roberts, A. Sharma, A. Gualberto, et al. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5834 - 5840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, K. A. Power, J. Mann, A. Cheng, and L. U. Thompson Flaxseed Alone or in Combination with Tamoxifen Inhibits MCF-7 Breast Tumor Growth in Ovariectomized Athymic Mice with High Circulating Levels of Estrogen Exp Biol Med, September 1, 2007; 232(8): 1071 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Giltnane, L. Ryden, M. Cregger, P.-O. Bendahl, K. Jirstrom, and D. L. Rimm Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor Positive Premenopausal Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3007 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fan, J. Wang, R. J. Santen, and W. Yue Long-term Treatment with Tamoxifen Facilitates Translocation of Estrogen Receptor {alpha} out of the Nucleus and Enhances its Interaction with EGFR in MCF-7 Breast Cancer Cells Cancer Res., February 1, 2007; 67(3): 1352 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson Growth factor receptor interplay and resistance in cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Sarwar, J-S Kim, J Jiang, D Peston, H D Sinnett, P Madden, J M Gee, R I Nicholson, A E Lykkesfeldt, S Shousha, et al. Phosphorylation of ER{alpha} at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER{alpha} phosphorylation in breast cancer progression. Endocr. Relat. Cancer, September 1, 2006; 13(3): 851 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M W Gee, A Howell, W J Gullick, C C Benz, R L Sutherland, R J Santen, L-A Martin, F Ciardiello, W R Miller, M Dowsett, et al. Consensus Statement Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S1 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R I Nicholson, I R Hutcheson, S E Hiscox, J M Knowlden, M Giles, D Barrow, and J M W Gee Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S29 - S36. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
